At ASH 2024, researchers presented findings from the RENOVE trial (NCT03285438), evaluating reduced-dose vs full-dose direct oral anticoagulants for patients at high risk of recurrent venous thromboembolism (VTE).
Key Findings:
Reduced-dose anticoagulation did not prove noninferior to full-dose in preventing recurrent VTE.
Clinically relevant bleeding and the composite risk of VTE recurrence or bleeding were lower with reduced-dose therapy.
Mortality rates and risk of arterial thromboembolic events did not increase with reduced dosing.
These results contribute to ongoing discussions about balancing efficacy and safety in long-term anticoagulation strategies for high-risk VTE patients.
Thanks to all the researchers for their contributions to this important study!
For more details:https://lnkd.in/exvPp9T9
